|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-4-2
|
|
pubmed:abstractText |
Ipilimumab is a monoclonal antibody that blocks the immune-inhibitory interaction between CTL antigen 4 (CTLA-4) and its ligands on T cells. Clinical trials in cancer patients with ipilimumab have shown promising antitumor activity, particularly in patients with advanced melanoma. Often, tumor regressions in these patients are correlated with immune-related side effects such as dermatitis, enterocolitis, and hypophysitis. Although these reactions are believed to be immune-mediated, the antigenic targets for the cellular or humoral immune response are not known.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BrowningJudyJ,
pubmed-author:CebonJonathanJ,
pubmed-author:ChenWeisanW,
pubmed-author:DavisIan DID,
pubmed-author:DimopoulosNektariaN,
pubmed-author:EbertLisa MLM,
pubmed-author:HoosAxelA,
pubmed-author:JacksonHeather MHM,
pubmed-author:KleinOliverO,
pubmed-author:LuescherImmanuel FIF,
pubmed-author:NicholaouTheoT,
pubmed-author:RussellSarah ESE,
pubmed-author:TanBee ShinBS,
pubmed-author:ZuberMarinaM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2507-13
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19318477-Antibodies, Monoclonal,
pubmed-meshheading:19318477-Antigens, Neoplasm,
pubmed-meshheading:19318477-Antineoplastic Agents,
pubmed-meshheading:19318477-Autoimmunity,
pubmed-meshheading:19318477-Cytotoxicity, Immunologic,
pubmed-meshheading:19318477-Double-Blind Method,
pubmed-meshheading:19318477-Exanthema,
pubmed-meshheading:19318477-Humans,
pubmed-meshheading:19318477-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:19318477-MART-1 Antigen,
pubmed-meshheading:19318477-Melanoma,
pubmed-meshheading:19318477-Neoplasm Proteins,
pubmed-meshheading:19318477-Skin Neoplasms,
pubmed-meshheading:19318477-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:19318477-Tomography, X-Ray Computed
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
|
|
pubmed:affiliation |
Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Heidelberg, Victoria, Australia.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
